Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet
Oramed Pharmaceuticals announced its inclusion in the Russell 2000 and Russell 3000 indexes, effective June 29, 2026, a move expected to enhance liquidity and broaden its shareholder base. The company highlighted a strengthened balance sheet with approximately $270 million in total cash and assets as of March 31, 2026, following a $10.5 million dividend payment in January.
Key figures
- Pelthos investment
- $1.5 million
- Scilex outstanding
- $43 million
- Scilex royalty rate
- 4%
- Alpha tau investment
- $38.2 million
- Scilex loan invested
- $99.5 million
- Pelthos exit proceeds
- $3.6 million
- Total cash and assets
- $270 million
- Alpha tau appreciation
- $128 million
- Alpha tau current value
- $167 million
- Scilex recouped to date
- $118 million
- Scilex minimum annual royalty
- $1.6 million
- Scilex total expected recovery
- $161 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.